Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 5,733,256 | 2,855,198 | 7,862,340 | 5,673,535 | 3,936,504 |
| Depreciation Amortization | 569,206 | 247,708 | 1,042,459 | 720,743 | 469,898 |
| Accounts receivable | N/A | N/A | -1,404,247 | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | 951,127 | N/A | N/A |
| Other Working Capital | -2,079,149 | -1,472,126 | -755,578 | -680,288 | 855,426 |
| Other Operating Activity | 4,307,612 | 2,665,417 | 3,474,298 | 3,998,656 | 1,537,393 |
| Operating Cash Flow | $8,530,925 | $4,296,197 | $11,170,400 | $9,712,646 | $6,799,221 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 493,964 | 69,456 | -413,614 | 558,654 | 451,737 |
| PPE Investments | -1,544,423 | -676,261 | -1,719,874 | -972,131 | -565,565 |
| Net Acquisitions | N/A | N/A | -1,001,820 | N/A | N/A |
| Purchase Of Investment | -1,097,211 | -340,220 | -23,930 | -894,333 | -702,273 |
| Sale Of Investment | 4,821 | 4,755 | N/A | -947 | N/A |
| Purchase Sale Intangibles | -184,817 | -15,563 | -369,151 | -188,744 | -57,200 |
| Other Investing Activity | -184,816 | -15,563 | -369,151 | -188,743 | -57,200 |
| Investing Cash Flow | $-2,327,665 | $-957,833 | $-3,528,389 | $-1,497,500 | $-873,301 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 1,504,536 | 1,590,160 |
| Debt Issued | N/A | N/A | 1,588,044 | N/A | 4,290 |
| Debt Repayment | -124,331 | -68,880 | -1,929,017 | -1,812,885 | -1,873,157 |
| Common Stock Repurchased | -2,048,614 | -749,176 | -3,410,578 | -2,238,809 | -1,705,561 |
| Dividend Paid | -2,679,036 | -2,642,362 | -3,582,905 | -3,423,496 | -2,243,670 |
| Other Financing Activity | 0 | 488,932 | 1 | 0 | 0 |
| Financing Cash Flow | $-4,851,981 | $-2,971,486 | $-7,334,455 | $-5,970,654 | $-4,227,938 |
| Exchange Rate Effect | -47,921 | -37,898 | -33,701 | 81,992 | 23,309 |
| Beginning Cash Position | 1,848,603 | 1,823,297 | 1,517,810 | 1,450,281 | 1,532,817 |
| End Cash Position | 3,151,961 | 2,152,278 | 1,791,665 | 3,776,764 | 3,254,108 |
| Net Cash Flow | $1,303,358 | $328,980 | $273,854 | $2,326,483 | $1,721,291 |
| Free Cash Flow | |||||
| Operating Cash Flow | 8,530,925 | 4,296,197 | 11,170,400 | 9,712,646 | 6,799,221 |
| Capital Expenditure | -1,544,423 | -676,261 | -1,719,874 | -972,131 | -565,565 |
| Free Cash Flow | 6,986,502 | 3,619,936 | 9,450,526 | 8,740,516 | 6,233,656 |